IL275948A - History of H2-indazole as CDK4 and CDK6 inhibitors and their medical uses - Google Patents

History of H2-indazole as CDK4 and CDK6 inhibitors and their medical uses

Info

Publication number
IL275948A
IL275948A IL275948A IL27594820A IL275948A IL 275948 A IL275948 A IL 275948A IL 275948 A IL275948 A IL 275948A IL 27594820 A IL27594820 A IL 27594820A IL 275948 A IL275948 A IL 275948A
Authority
IL
Israel
Prior art keywords
cdk4
therapeutic uses
indazole derivatives
cdk6 inhibitors
cdk6
Prior art date
Application number
IL275948A
Other languages
English (en)
Hebrew (he)
Original Assignee
Beta Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma Inc filed Critical Beta Pharma Inc
Publication of IL275948A publication Critical patent/IL275948A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL275948A 2018-01-29 2020-07-09 History of H2-indazole as CDK4 and CDK6 inhibitors and their medical uses IL275948A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862623516P 2018-01-29 2018-01-29
PCT/US2019/015547 WO2019148161A1 (en) 2018-01-29 2019-01-29 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
IL275948A true IL275948A (en) 2020-08-31

Family

ID=67394794

Family Applications (1)

Application Number Title Priority Date Filing Date
IL275948A IL275948A (en) 2018-01-29 2020-07-09 History of H2-indazole as CDK4 and CDK6 inhibitors and their medical uses

Country Status (15)

Country Link
US (1) US11352341B2 (cg-RX-API-DMAC10.html)
EP (1) EP3746072B1 (cg-RX-API-DMAC10.html)
JP (1) JP7337395B2 (cg-RX-API-DMAC10.html)
KR (1) KR20200115583A (cg-RX-API-DMAC10.html)
CN (1) CN111989099A (cg-RX-API-DMAC10.html)
AU (1) AU2019211491B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020015405A2 (cg-RX-API-DMAC10.html)
CA (1) CA3088381A1 (cg-RX-API-DMAC10.html)
EA (1) EA202091450A1 (cg-RX-API-DMAC10.html)
IL (1) IL275948A (cg-RX-API-DMAC10.html)
MX (1) MX2020007959A (cg-RX-API-DMAC10.html)
PH (1) PH12020551155A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202006748RA (cg-RX-API-DMAC10.html)
TW (1) TW201940166A (cg-RX-API-DMAC10.html)
WO (1) WO2019148161A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3070073A1 (en) 2017-07-18 2019-01-24 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
JP2020527588A (ja) 2017-07-18 2020-09-10 ニューベイション・バイオ・インコーポレイテッドNuvation Bio Inc. アデノシンアンタゴニストとしてのヘテロ環式化合物
WO2019161224A1 (en) 2018-02-15 2019-08-22 GiraFpharma LLC Heterocyclic compounds as kinase inhibitors
AU2019289176B2 (en) * 2018-06-18 2026-02-19 Adelaide university Gremlin-1 antagonist for the prevention and treatment of cancer
WO2020150674A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
US11254670B2 (en) 2019-01-18 2022-02-22 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
US20220079944A1 (en) * 2019-01-29 2022-03-17 Beta Pharma, Inc. 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases
TW202521536A (zh) * 2019-05-05 2025-06-01 美商基尼特奇公司 Cdk抑制劑
US12570633B2 (en) 2020-06-22 2026-03-10 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Preparation method for CDK4/6 inhibitor
US20230416271A1 (en) * 2020-11-26 2023-12-28 Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. Heteroarylquinazoline compounds as protein kinase inhibitors
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
DE602004017474D1 (de) 2003-07-11 2008-12-11 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
JPWO2006008874A1 (ja) * 2004-05-21 2008-05-01 萬有製薬株式会社 アミノチアゾ−ル骨格を有するCdk4、6選択的阻害剤
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
AU2009284098B2 (en) * 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
RU2670762C2 (ru) * 2013-12-31 2018-10-25 Хуаньчжу Фарма Ко., Лтд. Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака
WO2016014904A1 (en) * 2014-07-24 2016-01-28 Beta Pharma, Inc. 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
US9969719B2 (en) * 2015-03-11 2018-05-15 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug
CN107286134B (zh) * 2016-04-11 2019-04-12 上海勋和医药科技有限公司 2,4-二取代嘧啶衍生物作为cdk抑制剂及其应用

Also Published As

Publication number Publication date
CA3088381A1 (en) 2019-08-01
CN111989099A (zh) 2020-11-24
JP7337395B2 (ja) 2023-09-04
AU2019211491B2 (en) 2024-03-14
EP3746072B1 (en) 2023-04-12
EP3746072A4 (en) 2021-06-02
US11352341B2 (en) 2022-06-07
US20210139459A1 (en) 2021-05-13
EA202091450A1 (ru) 2021-01-14
EP3746072A1 (en) 2020-12-09
WO2019148161A1 (en) 2019-08-01
PH12020551155A1 (en) 2021-06-07
JP2021512161A (ja) 2021-05-13
SG11202006748RA (en) 2020-08-28
TW201940166A (zh) 2019-10-16
KR20200115583A (ko) 2020-10-07
BR112020015405A2 (pt) 2020-12-08
AU2019211491A1 (en) 2020-07-30
MX2020007959A (es) 2020-09-18

Similar Documents

Publication Publication Date Title
SG11202006748RA (en) 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
IL272948B1 (en) enpp1 inhibitors and their use for cancer treatment
MX2020008559A (es) Compuestos heterocíclicos como inhibidores de la quinasa.
IL268676A (en) Inhibition of smarca2 for treatment of cancer
EP3307728A4 (en) COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
EP3191469A4 (en) 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
HUE066693T2 (hu) CTPS1- gátló aminopirimidin- származékok
EP3280419A4 (en) Indazole and azaindazole btk inhibitors
MX381342B (es) Compuestos terapeuticos inhibidores.
IL261015A (en) History of methylamine as lysis oxidase inhibitors for cancer treatment
EA201591509A1 (ru) Ингибиторы cdc7
EP3195866A4 (en) Pharmaceutical composition for treating flt3 mutation-positive cancer, flt3 mutant inhibitor, and use of said pharmaceutical composition and said inhibitor
IL269710A (en) 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
MX395032B (es) Ciertos inhibidores de la proteína quinasa.
IL267829B (en) History of new amino-imidazopyridines as Janus kinase inhibitors and their pharmaceutical use
PL3679034T3 (pl) Pochodne 1-(4-(izoksazol-5-ilo)-1h-pirazol-1-ilo)-2-metylo-propan-2-olu i związki pokrewne jako inhibitory il-7 i ifn-gamma do leczenia chorób autoimmunologicznych i przewlekłego zapalenia
EP3113775A4 (en) Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer
IL274198A (en) Use of Nox inhibitors to treat cancer
EP3856352A4 (en) Methods of treatment of cancer comprising cdc7 inhibitors
MX2020000135A (es) Nuevos compuestos de quinolinona.
IL283687A (en) usp19 inhibitors and their use for therapeutic purposes
EP3654967A4 (en) USE OF EIBULIN AND CYCLINE-DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF CANCER
HK40052012A (en) Usp19 inhibitors for use in therapy
HK40061135A (en) Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
HK40058961A (en) Methods of treatment of cancer comprising cdc7 inhibitors